Results 151 to 160 of about 34,373 (228)

CYP2C9*1 Allele [PDF]

, 2020
openaire   +1 more source

Hypertension pharmacogenetics and limitations in Africa - a focus on the ACE, AGTR1 and CYP2C9 genes. [PDF]

J Hum Hypertens
Gomera RT, van Hougenhouck-Tulleken W, Brand SJ, van Niekerk C, Outhoff K.   +4 more
europepmc   +1 more source

CYP2C9*11 Allele [PDF]

, 2020
openaire   +1 more source

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants. [PDF]

Clin Transl Sci
Kim JD, Metzger IF, Lu JBL, Skaar TC, Desta Z.   +4 more
europepmc   +1 more source

CYP2C9*8 Allele [PDF]

, 2020
openaire   +1 more source

Computational variant predictors for pharmacogenomics: from evaluation of single alleles to assessment of adverse drug reactions to antidepressants. [PDF]

Pharmacogenomics J
Hajto J, Piechota M, Krätschmer I, Konowalska P, Boyle GE, Fowler DM, Borczyk M, Korostynski M.   +7 more
europepmc   +1 more source

CYP2C9*3 Allele [PDF]

, 2020
openaire   +1 more source

Genotipizacija CYP2C9 u kliničkoj praksi

, 2021
CYP2C9 jedan je od najvažnijih i najobilnije eksprimiranih enzima sustava citokrom P450 (CYP) u ljudskim jetrima. Odgovoran je za biotransformaciju oko 15 % klinički važnih lijekova, uključujući kumarinske antikoagulante (varfarin), antikonvulzive (fenitoin, valproična kiselina), oralne antidijabetike (gliklazid, tolbutamid), blokatore angiotenzinskih ...
openaire   +1 more source

CYP2C9*6 Allele [PDF]

, 2020
openaire   +1 more source

Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and Clinical Determinants of Fluoxetine-Norfluoxetine Pharmacokinetics in Real-World Clinical Conditions. [PDF]

Pharmaceutics
de la Cruz CG, Thomas L, Mata-Martín C, González I, LLerena A, Peñas-Lledó EM.   +5 more
europepmc   +1 more source